Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 164 for “"CETUXIMAB"”.
-
Cetuximab effect on human colon cancer stem cells
… tools for patient s therapeutic response. Cetuximab (Erbitux), currently in use for metastatic colorectal cancer, is a recombinant chimeric human:murine immunoglobulin IgG1 that binds to EGFR displacing its natural ligands. Cetuximab also induces receptor internalization and degradation. …
-
Combination of non-thermal atmospheric pressure plasma (NTP) with cetuximab inhibited invasion/migration of cetuximab-resistant oral squamous cell carcinoma (OSCC) cells
… the first time that combining NTP treatment with cetuximab led to inhibition of migration and invasion in cetuximab-resistant oral cavity squamous cell carcinoma (OSCC) cells, which could be a promising strategy to overcome resistance to anti-EGFR therapy. NTP induced deactivation of NF-κB in …
-
Immunologische Veränderungen bei Patienten mit akneiformem Exanthem unter Cetuximab-Therapie
Cetuximab ist ein monoklonaler Antikörper, der zunehmend in der Krebstherapie eingesetzt wird. Die typischste Nebenwirkung ist ein steriles makulo-papulöses Exanthem, das in vielen Studien positiv mit der Prognose korreliert. Auf die Therapie mit Cetuximab spricht jedoch nur ein begrenzter Anteil …
-
Verlauf von Magnesium- und Calciumwerten unter einer Therapie mit Cetuximab
… KRK und SCCHN etablierte Antikörper Cetuximab hat als häufige Nebenwirkungen Hypocalcämie, Hypomagnesiämie und ein akneiformes Exanthem. In der vorliegenden Arbeit wurde untersucht, ob die Verläufe der Serumspiegel von Magnesium und Calcium sowie das Auftreten eines akneiformen …
-
Immunologische Veränderungen bei Patienten mit akneiformem Exanthem unter Cetuximab-Therapie
Cetuximab ist ein monoklonaler Antikörper, der zunehmend in der Krebstherapie eingesetzt wird. Die typischste Nebenwirkung ist ein steriles makulo-papulöses Exanthem, das in vielen Studien positiv mit der Prognose korreliert. Auf die Therapie mit Cetuximab spricht jedoch nur ein begrenzter Anteil …
-
SYNTHESIS AND CHARACTERIZATION OF DOXORUBICIN CARRYING CETUXIMAB-PAMAM DENDRIMER BIOCONJUGATES
… drug doxorubicin, monoclonal antibody Cetuximab against EGF receptor, and polyethylene glycol (PEG). Doxorubicin was attached via an acid-sensitive hydrazon linkage to the dendrimer. Macromolecules are taken in by cells through endocytosis. pH inside the early endosomes to lysosomes …
-
Methylation of Egfr By Arginine Methyltransferase Prmt1 Enhances Egfr Signaling and Cetuximab Resistance
… of therapeutic EGFR monoclonal antibody, cetuximab. EGFR methylation level also correlates with higher recurrence rate after cetuximab treatment and poorer overall survival in colorectal cancer patients. These data suggest that R198/R200 methylation plays important role in regulating EGFR …
-
Proteomics uncover EPHA2 in cetuximab resistant colorectal cancer cell lines as a potential novel therapeutic target
… the anti-EGFR targeted monoclonal antibodies cetuximab (CET) or panitumumab. Despite the intensive therapy regimens, 5-year survival rates in metastatic disease are as low as 16%, owing to primary treatment resistance or the rapid development of acquired (or secondary) treatment resistance. …
-
Novel Functions of Cetuximab In Egfr-Targeted Therapy: Radiosensitization, Glycolysis Inhibition, and Cellular Redox Status Regulation
… of head and neck cancers. The anti-EGFR antibody cetuximab has been approved by the FDA for the treatment of head and neck cancers, however, only a small fraction of patients respond to cetuximab treatment. Further investigation to understand the mechanisms underlying cetuximab-mediated …
-
In vitro-Untersuchungen zur Wirksamkeit von Erlotinib, Gefitinib und Cetuximab bei der Behandlung des Kopf-Hals-Karzinoms
… Therapeutikum ist der monoklonale Antikörper Cetuximab, welcher eine gezielte Blockade des epidermal growth factor receptors (EGFR) bewirkt. Tyrosinkinaseinhibitoren (TKIs) wie Erlotinib oder Gefitinib, welche ebenfalls am EGFR angreifen, konnten in klinischen Studien bisher nicht den hohen …
-
Investigating the role of ADAM10 and ADAM17 in cetuximab resistance in head and neck squamous cell carcinoma
… head and neck squamous cell carcinoma (HNSCC). Cetuximab is the first and the only anti-EGFR monoclonal antibody which received approval from FDA for the treatment of HNSCC. However, most patients either do not respond to cetuximab or develop acquired resistance. The aim of my D.Phil. study was …
-
Analysis of the involvement of exosomal miRNAs and proteins in the response of CRC cells to Cetuximab
… di cancro al colon trattate dopo trattamento con cetuximab, un farmaco anti-tumorale diretto contro il recettore EGFR. In particolare, la via di EGFR è stata accostata alla biogenesi dei microRNAs e in aggiunta alla comunicazione intercellulare. Le due linee cellulari analizzate erano le Caco-2 …
-
MACHINE LEARNING-GUIDED PREDICTION OF FUNCTIONAL OUTCOMES OF EGFR EXTRACELLULAR DOMAIN MUTATIONS IN COLORECTAL CANCER: IMPLICATIONS FOR CETUXIMAB RESISTANCE
… worldwide. Monoclonal antibodies such as cetuximab which target the extracellular domain (ECD) of the epidermal growth factor receptor (EGFR), have improved outcomes for RAS wild-type metastatic CRC patients. However, resistance to these therapies frequently arises through somatic …
-
Pancreatic Ribonuclease Functions As An Epidermal Growth Factor Receptor Ligand Independently of Its Enzyme Activity and Contributes to Cetuximab Resistance
… Strikingly, hRNase5 also enhances resistance to cetuximab therapy in pancreatic cancer. Thus, there may be an interplay between serum RNase and overexpressed EGFR in human cancers, especially in pancreatic cancer, that leads to aggressive cancer behaviors. Our findings uncover a potential …
-
Análisis de decisión por múltiples criterios (MCDA); evaluación riesgo, beneficio y costo de cetuximab y bevacizumab en cáncer colorrectal metastásico
… among which we find anti-EGFR therapies such as cetuximab and panitumumab and anti-angiogenic therapies such as bevacizumab, which, combined with chemotherapy, have improved the efficacy outcomes in this population with safety and cost profiles characteristic of each one. A Risk-Benefit-Cost …
-
Molecular analyses of resistance and sensitivity mechanisms to anti-EGFR directed tumor therapy
… to the EGFR-targeting drugs, gefitinib and cetuximab. The examinations support the notion that response to gefitinib is neither exclusive nor strictly determined by the presence of EGFR kinase mutations. Yet, cells expressing EGFR kinase domain mutations tended to generally respond better to …
Page 1 of 9